Evidence map›Paper›PMID 36518706›Full record

ArticleACS medicinal chemistry letters2022

From Oxetane to Thietane: Extending the Antiviral Spectrum of 2'-Spirocyclic Uridines by Substituting Oxygen with Sulfur.

Sandrine Grosse, Abdellah Tahri, Pierre Raboisson, Yannis Houpis, Bart Stoops, Edgar Jacoby, Jean-Marc Neefs, Marnix Van Loock, Olivia Goethals, Peggy Geluykens and 2 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Oxetanes in Drug Discovery Campaigns.Journal of medicinal chemistry · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sandrine GrosseJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.ORCID https://orcid.org/0000-0003-4385-2206
Abdellah TahriJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Pierre RaboissonJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Yannis HoupisJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Bart StoopsJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Edgar JacobyJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Jean-Marc NeefsJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Marnix Van LoockJanssen Global Public Health, R&D, Turnhoutseweg 30, 2340 Beerse, Belgium.
Olivia GoethalsJanssen Global Public Health, R&D, Turnhoutseweg 30, 2340 Beerse, Belgium.
Peggy GeluykensCharles River, Discovery, Turnhoutseweg 30, 2340 Beerse, Belgium.
Jean-François BonfantiJanssen Research and Development, Chaussée du Vexin, 27100 Val de Reuil, France.
Tim H M JonckersJanssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In continuation of our efforts of finding novel nucleoside inhibitors for the treatment of viral diseases, we initiated a discovery research program aimed at identifying novel nucleos(t)ide inhibitors for emerging diseases like Dengue and Chikungunya. Based on the previously reported 2'-spiro-oxetane uridine derivatives active against Hepatitis C Virus (HCV), we envisaged its sulfur analogue as an interesting congener both from a synthetic as well as biological point of view. Surprisingly, we found the 2'-spirothietane uridine derivatives not only to be active against HCV and Dengue virus (DENV), viruses belonging to the flavivirus family, but also to demonstrate activity against alphaviruses like Chikungunya virus (CHIKV) and Sindbis virus (SINV).

Identifiers

PMID36518706
PMCPMC9743439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.